Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Roche

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

Dec 27, 2022

Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

Nov 07, 2022

Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape

Oct 31, 2022

Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market

Jul 22, 2022

A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment

Sep 09, 2021

Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm

Aug 25, 2021

Top 7 Pharma Industry Leaders in 2020 By the Numbers

Jul 24, 2021

Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

Mar 25, 2021

Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Mar 19, 2021

Navigating Through the Treatment Market Landscape of Head and Neck Cancers

Newsletter/Whitepaper